DENTSPLY SIRONA (NASDAQ: XRAY) has recently received a number of price target changes and ratings updates:

  • 12/13/2017 – DENTSPLY SIRONA was upgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “overweight” rating. They now have a $75.00 price target on the stock.
  • 12/8/2017 – DENTSPLY SIRONA is now covered by analysts at Deutsche Bank AG. They set a “buy” rating and a $81.00 price target on the stock.
  • 12/7/2017 – DENTSPLY SIRONA had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
  • 12/2/2017 – DENTSPLY SIRONA was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 11/30/2017 – DENTSPLY SIRONA was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $68.00 price target on the stock.
  • 11/28/2017 – DENTSPLY SIRONA is now covered by analysts at Stephens. They set an “overweight” rating and a $75.00 price target on the stock.
  • 11/6/2017 – DENTSPLY SIRONA had its price target raised by analysts at Stifel Nicolaus from $66.00 to $70.00. They now have a “buy” rating on the stock.
  • 11/6/2017 – DENTSPLY SIRONA had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
  • 11/6/2017 – DENTSPLY SIRONA was upgraded by analysts at Barrington Research from a “market perform” rating to an “outperform” rating. They now have a $73.00 price target on the stock.
  • 11/3/2017 – DENTSPLY SIRONA was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 10/30/2017 – DENTSPLY SIRONA was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Over the last year, DENTSPLY SIRONA traded below the broader industry in terms of prices. The company's higher capital expenditure on product development and tough competition are expected to put margins under pressure. Unfavorable foreign exchange rate and integration risks are the major headwinds in the near term. However robust performance by the company’s flagship dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic product platforms hold considerable promise over the long haul. Emerging markets like Asia-Pacific & the Middle East offer healthy growth opportunities on a long-term basis, as they remain vastly untapped with low dental products penetration. The company’s agreements with MedTech bigwigs like Henry Schein and Patterson Companies in Canada are likely to drive sales. DENTSPLY SIRONA has recently witnessed a rebound in sales in Asia, particularly Japan, and strong growth in Russia.”
  • 10/20/2017 – DENTSPLY SIRONA was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Over the last three months, DENTSPLY SIRONA traded below the broader industry in terms of prices. The company's higher capital expenditure on product development and tough competition are expected to put margins under pressure. Unfavorable foreign exchange rate and integration are the major risks in the near term. However robust performance by the company’s flagship dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic product platforms hold considerable promise over the long haul. Emerging markets like Asia-Pacific & the Middle East offer healthy growth opportunities on a long-term basis, as they remain vastly untapped with low dental products penetration. The company’s agreements with MedTech bigwigs like Henry Schein and Patterson Companies in Canada are likely to drive sales. DENTSPLY SIRONA has recently witnessed a rebound in sales in Asia, particularly Japan, and strong growth in Russia.”
  • 10/19/2017 – DENTSPLY SIRONA was given a new $63.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 10/19/2017 – DENTSPLY SIRONA had its “buy” rating reaffirmed by analysts at Stifel Nicolaus.

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) traded down $0.41 during trading on Friday, hitting $65.65. 937,100 shares of the stock traded hands, compared to its average volume of 1,647,865. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59. DENTSPLY SIRONA Inc. has a 1 year low of $52.53 and a 1 year high of $68.98. The company has a market capitalization of $15,172.85, a PE ratio of 26.32, a price-to-earnings-growth ratio of 2.62 and a beta of 1.31.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $978.99 million. During the same quarter last year, the business earned $0.66 earnings per share. The business’s revenue was up 5.8% on a year-over-year basis. analysts forecast that DENTSPLY SIRONA Inc. will post 2.65 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 12th. Stockholders of record on Friday, December 29th will be issued a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend is Thursday, December 28th. DENTSPLY SIRONA’s dividend payout ratio is -10.09%.

In other news, Director Francis J. Lunger sold 8,900 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $65.90, for a total value of $586,510.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Nicholas W. Alexos bought 50,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was purchased at an average price of $65.85 per share, for a total transaction of $3,292,500.00. The disclosure for this purchase can be found here. 1.99% of the stock is currently owned by company insiders.

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Receive News & Ratings for DENTSPLY SIRONA Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc and related companies with MarketBeat.com's FREE daily email newsletter.